Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Anavex Life Sciences Corp (AVXL)

Add AVXL Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, blanka, 123tom, kevindenver, TomP1, Rubyred77
Search This Board: 
Last Post: 12/11/2017 8:16:11 AM - Followers: 719 - Board type: Free - Posts Today: 53

Anavex Life Sciences Corp (AVXL)

Company website:
Company Address:
51 West 52nd Street, 7th floor
New York, NY
10019 USA

CIK:  0001314052

Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer.  The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.

Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease.  ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.  Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others.  The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial.  ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.

The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.

Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL


Patent Info:

Clinical Trials:
Recent News:
Company News Releases:
Share Structure:  See SEC filings
Investor Relations:

Marketing Details:


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVXL News: Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs 07:00 AM
AVXL News: Anavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of... 11/21/2017 07:00:00 AM
AVXL News: Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington... 11/08/2017 07:00:00 AM
AVXL News: Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2-73 at 2017 Clini... 11/04/2017 03:30:00 PM
AVXL News: Statement of Changes in Beneficial Ownership (4) 10/26/2017 02:50:54 PM
News News Alert: Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs 12/11/2017 07:00:00 AM
#133249  Sticky Note Fact: the company continues to use unambiguous polarbear77 12/07/17 12:00:43 PM
#131122  Sticky Note Has Anavex progressed too slowly and not kept Investor2014 11/20/17 07:44:47 AM
#129044  Sticky Note People seem to always lose track of the dadofmarcmax 11/06/17 10:58:33 AM
#116985  Sticky Note Anavex Life Sciences Corp. - Things To Know. nobrainerstocks 08/24/17 06:32:49 AM
#103034  Sticky Note To answer your good questions. falconer66a 04/26/17 10:18:09 AM
#133637   CAN YOU BELIEVE IT! McMagyar 12/11/17 08:16:11 AM
#133636   well especially with the Parkinson trial. anders2211 12/11/17 08:16:04 AM
#133635   What I don't get is the 3-trial promise kld2 12/11/17 08:10:02 AM
#133634   A lot dude. How many message boards do ExtremelyBullishZig 12/11/17 08:00:56 AM
#133633   what is clear is that Missling has been anders2211 12/11/17 07:59:30 AM
#133631   Anavex will host a conference call at 4:30 kld2 12/11/17 07:58:03 AM
#133630   What does trials starting in December or Q1 jtsmgoblue 12/11/17 07:57:08 AM
#133629   Conference call is just to offer false hope ExtremelyBullishZig 12/11/17 07:56:26 AM
#133628   I suspect we will see an uptick today. Investor2014 12/11/17 07:54:42 AM
#133627   Speaking of being right to the extend it Investor2014 12/11/17 07:53:35 AM
#133626   Yes congratulations on being right that a small brichnyc 12/11/17 07:51:13 AM
#133625   Yep time is money and I bet investors Investor2014 12/11/17 07:50:58 AM
#133624   I think one will find that the market jimmy667 12/11/17 07:50:27 AM
#133622   Suppose not. But I, for one, am not kld2 12/11/17 07:46:57 AM
#133621   Conference call might tell the story. If there riaguy 12/11/17 07:46:48 AM
#133619   Sure... ExtremelyBullishZig 12/11/17 07:45:29 AM
#133617   Well I knew that but some posters questioned Amatuer17 12/11/17 07:43:14 AM
#133616   I am expecting LPC to be tapped, just Investor2014 12/11/17 07:39:47 AM
#133615   Are you kidding me? It is a positive ExtremelyBullishZig 12/11/17 07:39:29 AM
#133614   well, whatever song you have been listening to kld2 12/11/17 07:38:07 AM
#133613   Ariana Pharmaceuticals milking their account for everything they've ExtremelyBullishZig 12/11/17 07:37:45 AM
#133612   News out. See you at 3. scottsmith 12/11/17 07:36:44 AM
#133611   Will surely hit my 3.30 buy target. Actually, kld2 12/11/17 07:36:32 AM
#133610   A prediction is that we will now start Investor2014 12/11/17 07:35:37 AM
#133609   Deceptive, if you ask me. Led retail on. kld2 12/11/17 07:34:57 AM
#133608   So how many investors do you think you nobrainerstocks 12/11/17 07:34:42 AM
#133607   It's not a home study. It home dosing. ExtremelyBullishZig 12/11/17 07:34:06 AM
#133606   Good for you, glad you are happy. Investor2014 12/11/17 07:31:17 AM
#133605   I am not impatient and disappointed but happy Amatuer17 12/11/17 07:29:37 AM
#133604   No pre-market trades yet ??? I'm surprised--I think plexrec 12/11/17 07:28:55 AM
#133603   Don't be so impatient or disappointed. Investor2014 12/11/17 07:27:57 AM
#133602   No will not start this year so Ragnaroc 12/11/17 07:26:35 AM
#133601   “Cash and equivalents of $27.4 million at September F1ash 12/11/17 07:26:33 AM
#133600   In Dr M we trust - he will Amatuer17 12/11/17 07:25:24 AM
#133599   Yes new fda guidelines can come now and Amatuer17 12/11/17 07:23:13 AM
#133598   also: anders2211 12/11/17 07:22:08 AM
#133597   We do not need to wait till Jan Amatuer17 12/11/17 07:21:35 AM
#133596   Ouch! The next couple weeks might fill that ExtremelyBullishZig 12/11/17 07:15:18 AM
#133595   Well what do you know I was right Ragnaroc 12/11/17 07:12:37 AM
#133594   and anders2211 12/11/17 07:11:50 AM
#133593   But...But...there is still time left in 2017. ExtremelyBullishZig 12/11/17 07:11:47 AM
#133592   As a long term investor, this update is Investor2014 12/11/17 07:11:10 AM
#133591   The Company filed an IND for ANAVEX®2-73 in anders2211 12/11/17 07:08:50 AM
#133590 anders2211 12/11/17 07:06:27 AM
#133589   So no 3 trials starting in 2017. Not even TomP1 12/11/17 06:59:19 AM
#133588   Hopefully this will be anavex in a few Penny Double 12/11/17 05:51:36 AM
#133587   This is a good time to point out tradeherpete 12/11/17 02:56:06 AM
#133586 Informative article on ye Investor2014 12/11/17 02:52:34 AM
#133585   The rules on generics have changed. They can Steady_T 12/11/17 01:07:56 AM
#133584   I was thinking the same thing, brother! ExtremelyBullishZig 12/10/17 10:35:10 PM